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Background: Transformation of B-cell chronic lymphocytic leukaemia (B-CLL) to diffuse large B cell lymphoma
(DLBCL) (Richter’s syndrome (RS)) is a rare (2-15% of patients) but catastrophic complication of B-CLL. Dose-intense
chemotherapy regimens investigated in small single institution trials, but with the exception of bone marrow
transplantation for a minority of patients, little has improved the median overall survival of patients with RS beyond
eight months. Patients are often elderly, immunosuppressed, possess co-morbidities and have a deteriorating
performance status. TP53 disruption is a common molecular abnormality noted in RS and contributes to the
tumour’s chemotherapy resistance. Ofatumumab is a fully human anti-CD20 monoclonal IgG1κ antibody that targets a
unique epitope on B lymphocytes. It has displayed increased binding affinity and a longer dissociation time when
compared to rituximab resulting in improved complement dependent cellular cytotoxicity (CDCC); a mechanism with
the potential to overcome apoptosis-resistance in TP53 disruption. Given the prevalence of TP53 disruption in RS,
Ofatumumab was considered a relatively non-toxic agent with a sound rationale to test in a prospective multicentre
trial as an adjunct to CHOP induction and subsequent ofatumumab maintenance therapy in responding patients.
Methods/Design: The CHOP-OR study is a prospective phase II study to evaluate the safety, feasibility and activity of a
CHOP chemotherapy in combination with ofatumumab in induction and subsequent maintenance for patients with
newly diagnosed RS. The primary objective will be the overall response rate (ORR) in patients with RS after six cycles of
CHOP-O. The secondary objectives include feasibility of recruitment, progression free survival (PFS), overall survival (OS)
and toxicity. The study will be accompanied by exploratory analysis of the genomic landscape of RS in newly
diagnosed patients.
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Discussion: The CHOP-OR trial evaluates the safety, feasibility and activity of CHOP plus Ofatumumab induction and
Ofatumumab maintenance in new RS patients. The study is currently recruiting and has met the interim analysis criteria,
with more than 7 of the first 25 participants achieving a CR or PR after six cycles of CHOP-O. The study has the potential
to identify predictive biomarkers for this treatment modality.
Trial registration: NCT01171378.
Keywords: Ofatumumab, CHOP, TP53, Richter’s syndrome, Chronic lymphocytic leukaemia, Diffuse large B cell
lymphoma, Phase II, Rare cancersBackground
B-CLL is the most prevalent chronic lymphoproliferative
disease and follows a typically indolent course, however
2-15% of patients [1-3] transform to an invariably
aggressive, chemo-resistant high-grade non-Hodgkin’s
lymphoma (NHL) [4]. This high-grade transformation
of CLL was first recognised in 1928 by Maurice Richter
who described an aggressive, life-threatening presenta-
tion of rapidly fatal generalized lymphadenopathy and
hepatosplenomegaly [4] that he called a “reticular cell
sarcoma” arising in a patient with B-CLL. Whereas all
subtypes of NHL taken together represent the fifth
most common cancer type in the world and its incidence
continues to increase [5], Richter’s syndrome (RS) is rare
and characterised by disproportionate weight loss, rapidly
growing and/or asymmetrical lymphadenopathy or extra-
nodal fluorodeoxyglucose ([18F] FDG) positron-emission-
tomography (PET) CT-avid masses, new B symptoms, a
rapidly rising lactate dehydrogenase (LDH), or new hyper-
calcaemia in a patient with known B-CLL. The vast major-
ity of RS represent transformations to an activated B-cell
type (ABC) diffuse large B-cell lymphoma (DLBCL)
(90-95%) with a small proportion transforming to Hodgkin’s
lymphoma [6]. The prognosis of de novo DLBCL has
much improved over the last 15 years with the introduc-
tion of the anti-CD20 monoclonal antibody rituximab to
an anthracycline based regimen, typically CHOP (cyclo-
phosphamide, doxorubicin, oncovin (vincristine), prednis-
olone) such that the long term survival in those fit for
anthracycline-based therapy is approaching 70% [7]. Un-
fortunately, the same cannot be said for DLBCL-Richter’s
syndrome. RS can present in either heavily pre-treated,
immunosuppressed or in untreated B-CLL patients [8].
Patients typically present with a deteriorating performance
status. The median age of B-CLL diagnosis is 72 years [9],
and therefore patients often possess dose-limiting co-
morbidities. Given its rarity, no multicentre randomised
controlled trials have been performed. Alkylator, anthracy-
cline, platinum and purine analogue chemotherapy have
formed the backbone of a number of regimens trialled in
RS. R-CHOP (cyclophosphamide, doxorubicin, vincristine,
and prednisone with rituximab) [7], R-hyper-CVXD-MA
[10] (fractionated cyclophosphamide, vincristine, liposomaldaunorubicin, and dexamethasone plus rituximab and alter-
nating with methotrexate and cytarabine with rituximab),
hyper-CVXD alone [11], FACPGM (fludarabine, cytarabine,
cyclophosphamide, cisplatin and GM-CSF) [12], OFAR1
[13] and OFAR2 [14] (oxaliplatin, fludarabine, cytarabine,
rituximab and pegfilgrastim) [2] treatment regimens have
been used. The best response rates are 41% with hyper-
CVXD and R-hyper-CVXD-MA and 50% with OFAR1,
although responses are short-lived. Moreover, these reg-
imens are toxic and inappropriate for many patients
with RS. The median survival of 8–10 months [2] from
diagnosis has generally not been bettered in the litera-
ture. Recent published data using R-CHOP in 15 patients
with Richter’s Syndrome showed an overall response rate
of 67% but the progression free survival (10 months) and
overall survival (21 months), although an improvement,
was still short and the study number was very small [15].
Autologous and allogeneic bone marrow transplantation
are reserved for younger patients with good performance
status [8].
Ofatumumab is a fully humanised monoclonal IgG
anti-CD20 antibody. It specifically and powerfully targets
a unique CD20 epitope on B cells. When compared with
rituximab, it binds with increased affinity and has a
longer dissociation time, both of which improves its
complement-mediated cellular cytotoxicity [16,17]. As
a result, ofatumumab has a greater potential to induce
B cell apoptosis independently of p53 than rituximab,
and has been shown to be efficacious and non-toxic in
relapsed B-CLL refractory to fludarabine and alemtu-
zumab; a group that commonly possess TP53 muta-
tions and/or deletions [18]. Given the high incidence
of TP53 disruption in patients with DLBCL-RS [19]
and that patients characteristically relapse early after initial
response to induction, it was felt that ofatumumab as in-
duction (alongside CHOP) and maintenance therapy
would represent both a pragmatic and biologically-sound
treatment for patients with RS within this phase II clinical
trial. As many clinicians treat DLBCL-RS with R-CHOP
outside of a clinical trial, the National Cancer Research In-
stitute (NCRI) UK-based “CHOP-OR” single arm, multi-
centre study was therefore designed to investigate whether
DLBCL-RS treated with six cycles of CHOP-O followed
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48 weeks in responding patients was feasible and im-
proved clinical efficacy over and above R-CHOP.
Methods/Design
Study design
The Study of CHOP with Ofatumumab in Patients with
Richter’s Syndrome (CHOP-OR) trial is a single arm,
multi-centre, non-randomised phase II NCRI feasibility
study in 35 patients with newly diagnosed Richter’s Syn-
drome, recruiting from 10 centres in the UK since April
2011. Following eligibility confirmation, consent and
then screening procedures, eligible patients will receive
CHOP-O for six cycles, followed by six cycles of ofatu-
mumab maintenance treatment every eight weeks, and
then a three month follow-up period. The total duration
of treatment and follow up for an individual participant
is therefore 72 weeks; 20 weeks for induction/consolida-
tion therapy, 40 weeks of maintenance, and 12 weeks of
follow-up. The total duration of the trial is estimated to
be four years. Any patients who withdraw from the study
and are not evaluable will ideally be replaced, if within
the recruitment period. It is possible that some clinicians
will choose to perform autologous stem cell transplant-
ation on responding patients prior to or following main-
tenance treatment. Data on outcome will be collected in
these patients.
The primary objective of the CHOP-OR study is to de-
termine objective response to Ofatumumab plus CHOP
at week 20 as measured from start of treatment according
to the Revised Response Criteria for Malignant Lymph-
oma (Cheson Criteria) [20]. Secondary objectives include
assessing the feasibility of recruitment, progression free
survival (PFS) and overall survival (OS), the clinical benefit
and changes in patient-reported outcomes (PROs), safety
and tolerability.
The CHOP-OR trial is an investigator initiated trial,
and is sponsored by The University of Oxford. The trial
has been designed through collaboration with the Oxford
Clinical Trials Research Unit (OCTRU), the Oncology
Clinical Trial Office (OCTO), the Centre for Statistics in
Medicine (CSM) and the Department of Haematology and
Oncology at the Oxford University Hospitals NHS Trust,
in cooperation with the National Institute of Health and
Research (NIHR) and the other participating trial sites.
The trial is coordinated by OCTO who are responsible for
the overall trial management, including; trial registration,
all trial-related meetings, database management, moni-
toring reporting and quality assurance. Data collection
is through electronic submissions of data by site staff
via the web-based data capture system OpenClinica.
Central and on-site monitoring is performed in accordance
with Good Clinical Practice (GCP) guidelines throughout
the trial. The centre for Statistics in Medicine (CSM),University of Oxford, will be responsible for all statis-
tical analysis.
The final protocol was approved by the National
Research Ethics Service (NRES) South Central – Oxford
Committee, the Medicine and Healthcare products Regu-
latory Agency (MHRA) and by Research and Develop-
ment departments of the other participating centres. The
CHOP-OR trial is run in accordance with the principles of
the Declaration of Helsinki (1996), UK Clinical Trials Reg-
ulations, the International Conference on Harmonisation
guidelines of Good Clinical Practice (GCP) and the applic-
able policies of the sponsoring NHS Trust.
Patient selection
To be eligible for inclusion in the CHOP-OR study,
patients must be over 18 years of age with an ECOG
Performance Status of 0–3, have a known diagnosis of
B-CLL and a newly diagnosed, untreated and biopsy
proven DLBCL Richter’s transformation according to the
World Health Organization (WHO) classification. The
histology results are to be reviewed locally in the first in-
stance and for study inclusion. This is in an attempt to
replicate the ‘real life’ scenario. The Biomedical Research
Centre (BRC) Oxford Molecular Diagnostic Centre
(MDC) will provide a central review of histopathology
diagnostic samples during the study. Patients require a
standard Computerised Tomography (CT) scan to be
performed within 8 weeks prior to starting therapy. Pa-
tients will not be eligible if they have been previously
treated with anthracycline-containing treatment for
DLBCL within six months prior to registration, or have
central nervous system involvement with RS or B-CLL,
major medical co-morbidities, active and uncontrolled
infection including HIV, active hepatitis B or C or
other malignancy requiring active treatment (except
treated basal cell carcinoma and non-invasive squamous
cell carcinoma of the skin). Patients must use adequate
contraception before entry and throughout the study if
appropriate and women of childbearing potential must
be willing to use adequate contraception during study
and for 12 months after the last dose of ofatumumab.
Adequate contraception is defined as abstinence, hor-
monal birth control or intrauterine devices. Pregnant
patients or those breastfeeding are excluded, as well as
those patients who are considered non-compliant with
the CHOP-OR protocol, or those currently participating
in any other interventional clinical study.
A total of 10 NHS Hospital Trusts in the UK are partici-
pating in this clinical trial. The centres are (listed alphabet-
ically according to town or city): Queen Elizabeth Hospital,
Birmingham; Royal Bournemouth Hospital, Bournemouth;
Addenbrooke’s Hospital, Cambridge; St James’s University
Hospital, Leeds; Royal Liverpool University Hospital,
Liverpool; St Bartholomew’s Hospital, London; King’s
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Manchester; Nottingham City Hospital, Nottingham;
Churchill Hospital; Oxford.
Informed consent
Written and verbal versions of the participant informa-
tion sheet and informed consent will be presented to the
participants by the attending investigator detailing no
less than: the exact nature of the study; the implications
and constraints of the protocol; the known side effects
and any risks involved in taking part. It will be clearly
stated that the participant is free to withdraw from the
study at any time for any reason without prejudice to fu-
ture care, and with no obligation to give the reason for
withdrawal. The investigator will not undertake any
study specific procedures until valid consent is obtained.
Interventions
All patients will be treated with up to a maximum of six
three-weekly cycles of CHOP-O. This consists of:
cyclophosphamide 750 mg/m2 intravenous (iv) bolus,
doxorubicin 50 mg/m2 iv bolus, vincristine 1.4 mg/m2
(maximum 2 mg or 1 mg in patients over 70 years old)
iv infusion in 50 ml sodium chloride 0.9% over 10 mi-
nutes, prednisolone 40 mg/m2 orally od, on day one
and prednisolone 40 mg/ m2 orally od on days 2–5 of
each cycle. Mesna prophylaxis is recommended in
those with pre-existing bladder disorders. Ofatumumab
300 mg iv is given on day one of cycle one and 1000 mg iv
is given on day 8 and 15 of cycle one as loading doses and
then 1000 mg iv on day one of cycles 2–6. 1000 mg dosing
was chosen on the basis of available pre-clinical [20] and
clinical data [21] at the time of study design.
Maintenance ofatumumab 1000 mg iv is given every
eight weeks for a maximum of 6 cycles, and started four
weeks after day one, cycle six in those patients achieving
at least a partial response according to the Cheson criteria
after induction [22]. Ofatumumab infusion-related adverse
effects such as allergic and anaphylactoid reactions are
treated promptly as per the investigator’s discretion.
Pre-treatment assessment
Potential participants with a new diagnosis of Richter’s
transformation will receive a complete work-up which
includes a CT scan of the neck, chest, abdominal and
pelvis (NCAP), a bone marrow aspirate and trephine bi-
opsy (BMAT) and routine haematology, biochemical and
virology testing. In centres where it is feasible a PET CT
is recommended at baseline. A CT NCAP is repeated
after cycle six of CHOP-O and a BMAT repeated at this
stage, at the end of week 72 and at progression if the
bone marrow was involved at diagnosis with DLBCL. If
patients decline treatment within the CHOP-OR trial, an
adequate alternative treatment regimen, typically six cyclesof CHOP-R without maintenance rituximab is offered.
There is no availability of ofatumumab post-trial. Patients
will be seen by their clinician according to standard care.
Primary and secondary outcomes
The primary objective of the trial is to determine the ob-
jective response rate (ORR) of ofatumumab plus CHOP
according to the Revised Response Criteria for Malignant
Lymphoma (Cheson criteria) [22] as measured after in-
duction. Response assessment is made after cycle six or if
the patient withdraws from treatment earlier than cycle
six, their response recorded at withdrawal will be used to
determine the primary response. Or if an assessment is
not performed at withdrawal, the latest disease response
(e.g. post cycle four assessment) will be used. Patients will
be classified as responders/non-responders as follows:
complete remission (CR), partial remission (PR) or nodu-
lar partial remission (nPR) as responders while stable dis-
ease (SD) and progressive disease (PD) as non-responders.
Evaluable patients are those who have received at least 1
full cycle of CHOP-O and had a response assessment
(CT/PET scan or physical examination as appropriate).
The secondary objectives are to demonstrate feasibility of
recruitment in this rare disease, evaluate overall survival
(OS), progression free survival (PFS), duration of response,
time to next Richter’s therapy, constitutional symptoms
(B-Symptoms), minimal residual disease (MRD), Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus, patient reported outcome (PROs) and quality of life
measures, safety, and toxicity. OS is defined in whole days
as time from entry until death from any cause. Patients
alive during the course of the trial will be censored at their
last known follow-up date. PFS is defined in whole days as
time from entry until lymphoma progression or death
from any cause. Patients that are alive having not pro-
gressed during the course of the trial will be censored at
their last known progression-free follow-up date. Duration
of response is defined in whole days as the time between
recorded response to disease progression or death from
any cause. Patients who have not progressed or died will
be censored at the date of their last follow-up visit at
which the response was assessed. Time to next RS therapy
is defined as the time from the end of study treatment and
the start of the next RS therapy other than CHOP-O. Pa-
tients will be censored at the date of their last follow-up
visit at which further treatment was assessed.
Constitutional symptoms (B symptoms) are defined as
experiencing night sweats (in the absence of infection),
unexplained unintentional weight loss ≥ 10% within the
previous six months, extreme fatigue and recurrent and
unexplained fever of >38°C for twice weeks, and will be
evaluated at baseline and regular follow-ups. ECOG
performance status will be summarised at baseline and
regular follow-ups throughout the trial. Patient reported
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Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 and the EORTC QLQ-CLL16 at
baseline and regular follow-up visits throughout the
trial.
Statistical design
Sample size determination and power
Simon’s minimax two-stage design was implemented to
calculate the required sample size to identify a desired
response of the trial drug of 47% with a power of 80%
and significance of 20%. The study plans to accrue 25
patients in the first stage and 35 patients in total. The
number of cycles of CHOP-O will depend on the as-
sessment of activity and toxicity of the regimen by the
investigator in each patient. If at least 16 responses are
observed amongst 35 evaluable patients after six cycles
of CHOP plus ofatumumab, efficacy will be considered
to be equivalent or better than CHOP-R [7,10] and a
phase II trial extension or a randomised study might
be considered. The treatment will be considered inef-
fective if 33% or fewer patients achieve a response (PR
or CR).
Statistical analysis
The primary analysis will be performed on all patients
recruited who received at least one full cycle of CHOP-
O and had a response assessment by either clinical
examination or CT scan. A sensitivity analysis will be
performed using the per-protocol population defined as
those patients not deviating from the protocol in such a
manner that the assessment of efficacy endpoints may
be biased. The safety population (all patients who receive
at least one dose of the trial treatment) will be used to
evaluate all safety endpoints. The primary analysis will
report the proportion of responders after cycle six, in-
cluding exact two-sided 95% confidence intervals. The
analysis will also be reported at two further time points;
after cycle four and at 72 weeks. OS, PFS, time to next
Richter’s therapy and duration of response will be pre-
sented using Kaplan Meier plots and the time to event
will be summarised using medians together with their
two-sided 95% confidence intervals. Constitutional symp-
toms will be summarised at baseline and regular follow-
ups throughout the trial. Patient reported outcomes will
be presented using descriptive statistics for the EORTC
pre-defined functions and scales at baseline and different
follow-up time points. These will also be presented using
longitudinal methods for individual patient outcomes.
Frequency of number of adverse events (AEs) and the
number of patients reporting AEs will be summarised
overall and by system body class for SAEs, AEs with
CTCAE grade ≥1, AEs with CTCAE grade ≥3 and AEs
related to ofatumumab.Exploratory analysis
In addition to the safety and efficacy analysis, we will
perform an exploratory analysis in this well annotated,
prospectively collected patient data set. We will centrally
review pathology on all patients and PET CT scan re-
sults within the preceding eight weeks of the start of
study treatment. We are interested in correlating SUV
max values with histopathological findings. Gene muta-
tional analysis on all patients will be carried out on all
patients and will correlate abnormalities found with
clinical phenotype. Neither clonality data collected nor
patient individual characteristics will be used to influ-
ence the treatment option for the patients prospectively.Monitoring committee
There is no Data and Safety Monitoring Committee for
CHOP-OR; instead an Independent Trial Steering Com-
mittee (ITSC) is in place to monitor the safety and pro-
gress of the trial. The ITSC will meet approximately
twice per year. The ITSC, with an independent chair,
will provide overall supervision of the trial, in particular
trial progress, adherence to protocol, patient safety and
consideration of new information.Safety, discontinuation of treatment and premature
termination of the trial
Safety and tolerability will include serious adverse events
(SAEs) and adverse events (AEs), evaluated for grade,
duration, type, onset, and relationship to study investiga-
tional medicinal product (IMP) according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events V4.0 (NCI-CTCAE). AEs related to
ofatumumab will be assessed against the Investigators
Brochure (IB), and AEs related to the other drugs
(non-IMPs) will be assessed against the relevant Summary
of Product Characteristics (SPC). The investigator or site
staff are responsible for detecting, documenting and
reporting events that meet the definition of an AE or SAE
to the CHOP-OR Trial Office.
Patients must receive no further treatment on trial if
at either the post cycle four or six assessment, their
disease response is less than a PR. Patients may be with-
drawn from the trial at any time if it is the wish of the
patient for any reason, if the investigator judges it neces-
sary due to medical reasons, or if the patient becomes
pregnant. Patients may withdraw consent at any time; in
this event, any samples and data that have already been
provided for the research trial will be retained and used
in the analysis. No further samples will be taken and any
surplus material will be destroyed.
The Sponsor, CHOP-OR Trial Office (OCTO) and
the CI reserve the right to temporarily suspend or ter-
minate the study at any time for reasons including (but
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Confidentiality, dissemination of results and publication
policy
Information collected during the trial is considered
strictly confidential and will be securely stored with re-
stricted access in accordance with the Data Protection
Act. To protect the participant’s identity, only initials
and date of birth along with an assigned trial number
will be used as patient identifiers. It is clearly stated in
lay terms in the patient information sheet and as a sep-
arate point within the consent form that authorised staff
from the local Trust R&D office, the research team
based at each study site, OCTO personnel during on site
monitoring visits, and auditors from regulatory bodies
may have access to their patient records.
The Sponsor recognises that participating investigators
have a responsibility under the Research Governance
Framework for Health and Social Care to ensure that
results of scientific interest arising from the Study are
appropriately published and disseminated. The Chief
Investigator will ensure public disclosure of the clinical
trial research results in the form of a peer reviewed scien-
tific journal publication and for other academic research
purposes as appropriate. Participating site investigators
will be provided with the full summary of results and en-
couraged to share the summary of results with study par-
ticipants, as appropriate.
Interim analysis
To assess feasibility of recruitment, the recruitment rate
is being monitored closely. If less than 10 patients had
been recruited into the study within 12 months of open-
ing the first site to recruitment the study was to be
stopped because it was deemed not feasible to recruit
this patient population. This milestone was passed. Next,
response of the first 25 evaluable patients was assessed
at the post cycle six assessment or at the time of with-
drawal for those patients not completing cycle six of
treatment. As seven or more patients were found to have
achieved CR or PR, a further 10 patients are planned to
be recruited as stated in the protocol. If any of these fur-
ther 10 patients withdraw from the study and are not
evaluable then they will ideally be replaced, if within the
recruitment period. Statistical analyses will be under-
taken using STATA/SAS.
Discussion
The CHOP-OR trial evaluates the safety, feasibility and
clinical activity of ofatumumab induction combined with
CHOP and subsequent maintenance therapy in RS. The
potent anti-CD20 activity of ofatumumab, together with
its tolerability and efficacy in TP53 disruption provides aclear rationale for the study. The CHOP-OR study will
also aim to provide further genotype-phenotype matched
data to add to this growing field of interest in RS-DLBCL.
Encouragingly, the interim analysis showed that seven or
more patients achieved a CR or PR after induction
CHOP-O and therefore the trial is continuing to full
recruitment.Trial registration
ClinicalTrials.gov Identifier NCT01171378.Ethical approval
Obtained from the National Research Ethics Service
(NRES) Committee South Central – Oxford A. REC refer-
ence number: 10/H0604/85. UK CLL BioBank has ethical
approval to collect samples from all NCRN associated
clinical studies.
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